BioLineRx Receives Notice of Allowance from USPTO

BioLineRx (NASDAQ: BLRX) announced today that a Notice of Allowance has been received
from the United States Patent and Trademark Office (USPTO) claiming the
crystalline form of BL-1020, a first-in-class orally available treatment
for schizophrenia. The patent, when granted, will be valid at least
until 2031, without taking into account any possible extension periods,
which is nine years longer than the granted patent coverage previously
reported by the Company. Corresponding patent applications are pending
in Europe, Japan, India, China, Brazil, Mexico, Canada, Australia and
Israel.

"We are extremely pleased with the allowance of the patent covering
BL-1020's crystalline form by the USPTO. There is now a significantly

See full press release